Chan Beals

Directeur Technique/Scientifique/R&D chez Abide Therapeutics, Inc.

Health Technology

Finance

Postes actifs de Chan Beals

Sociétés	Poste	Début	Fin
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Directeur Technique/Scientifique/R&D	06/01/2016	-

Massachusetts Institute of Technology

Undergraduate Degree

Internationale

Etats-Unis

Opérationnelle

Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Sectorielle

Health Technology	2
Finance	2

Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Entreprise privées	1
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Health Technology

Entreprise privées

Health Technology